[Event Report] Intractable Disease Day Symposium: Future Measures for Intractable Diseases from the Perspectives of Patients and Citizens (May, 23 2024)
date : 8/23/2024
Tags: Other activities
*The event report has been published. (August 23, 2024)
*A Recording has been released on the following pages. (June 20, 2024)
Health and Global Policy Institute (HGPI) held an Intractable Disease Day Symposium: Future Measures for Intractable Diseases from the Perspectives of Patients and Citizens on 23rd May.
Although health policy spans a wide variety of topics, intractable diseases are one of the most important. While they are often discussed alongside rare diseases, certain aspects of intractable diseases place particularly heavy physical and psychological burdens on patients. We have yet to identify the underlying mechanisms or establish clear treatment methods for intractable diseases. They also require patients to undergo long-term treatment. Japan currently designates 341 conditions as “intractable diseases” and they are estimated to affect over 1 million people.
Starting the compilation of the “Outline of Intractable Disease Measures” in 1972, the Government of Japan has been advancing measures for intractable diseases through the promotion of R&D, improving the healthcare provision system, and supporting patients, mainly through the subsidization of care. After the formation of the Liaison Council for Intractable Disease Treatment and establishment of Intractable Disease Support Centers in each prefecture in 1998, joint efforts with the welfare system have been underway to improve living environments and provide employment support for people living with intractable diseases. The Long-Term Care Insurance System has made it possible to provide long-term care to people who require it due to an intractable disease, and a direction for intractable disease measures that include promoting healthcare and improving the social environment was set by the enactment of the Act on Medical Care for Patients with Intractable Diseases in 2014.
However, measures for intractable diseases face a number of lingering issues. For the healthcare provision system, these include information disparities, in which people do not receive enough of the information they need; long diagnostic delays or diagnosis lag; regional healthcare disparities; and collaboration spanning pediatric healthcare to adult healthcare. There are also a number of actions that should be taken for R&D. For example, we hope to see the establishment of a data aggregation system to further basic research on each disease as well as the promotion of Patient and Public Involvement (PPI) to encourage research that reflects patients’ needs in the development of therapeutics.
At this symposium, we held a multi-stakeholder discussion on the nature of intractable disease control to identify issues to address in the future and disseminate those issues to greater society.
■Recording of the Sympojium (2h 08min)
[Event Overview]
- Date & Time: Thursday, May 23, 2024; 15:00 – 17:00 (Open 14:45)
- Format: Hybrid in-person and online format
- Venue: Global Business Hub Tokyo Field (Grand Cube 3F, Otemachi Financial City, 1-9-2, Otemachi, Chiyoda-ku, Tokyo, JAPAN 100-0004)
- Language: Japanese and English (with simultaneous interpretation)
- Participation Fee: Free
- Organizer: Health and Global Policy Institute (HGPI)
- Supported by: Japan Patients Association (JPA); NPO ASrid
[Program] (titles omitted)
15:00-15:05 | Opening Remarks: Marking the Occasion for Intractable Disease Day |
Kunio Tsuji (Standing Director, JPA) |
|
15:05-15:20 | Presentation 1: The Past and Future of Measures for Intractable Diseases From the Viewpoint of Civil Society |
Yukiko Nishimura (President, NPO ASrid) | |
15:20-15:35 | Presentation 2: Measures for Intractable Diseases in Japan |
Masaaki Yokota (Deputy Director, Intractable Disease Control Division, Public Health Bureau, Ministry of Health, Labour and Welfare (MHLW)) |
|
15:40-15:55 | Presentation 3: Current Status and Future Prospects for Research in Intractable Diseases |
Tadayoshi Nakashima (Research Officer, Intractable disease/Rare disease, Rare/Intractable Disease Project, Division of Strategic Planning and Evaluation, Department of Innovative Drug Discovery and Development, The Japan Agency for Medical Research and Development (AMED)) |
|
15:55-16:10 | Presentation 4: Intractable Disease Measures from Local Governments |
Shizuko Tsushima (Director, Cancer and Disease Control Division, Healthcare and Medical Services Department, Health and Medical Services Bureau, Kanagawa Prefectural Government) | |
16:10-16:25 | Presentation 5: Co-creating Research with Patients and Citizens |
Atsushi Kogetsu (Assistant Professor, Department of Biomedical Ethics and Public Policy, Graduate School of Medicine, Osaka University) |
|
16:30-17:00 | Panel Discussion: The Future of Intractable Disease Control from the Perspectives of Patients and Citizens |
Panelists Moderator |
Top Research & Recommendations Posts
- [Survey Report] Survey of Japanese Nursing Professionals Regarding Climate Change and Health (Preliminary Version) (September 11, 2024)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Research Report] Building a Mental Health Program for Children and Measuring its Effectiveness (June 16, 2022)
- [Research Report] 2019 Survey on Healthcare in Japan
- [Announcement] A Turning Point Towards Building Green Healthcare Systems (June 5, 2024)
- [Research Report] The 2023 Public Opinion Survey on Satisfaction in Healthcare in Japan and Healthcare Applications of Generative AI (January 11, 2024)
- [Policy Recommendations] Achieving Equity in Multidisciplinary Pain Treatment and Support Systems for Pain Management (March 31, 2023)
- [Announcement] A Significant Step Towards the Building a Green Healthcare System: Support for the Formal Expression of Interest by the Japanese Government Delegation to the ATACH at the Executive Board Meeting of the WHO (February 16, 2024)
- [Policy Recommendations] Three Necessary Perspectives for Formulating the Basic Plan for the Promotion of Policies on Dementia: Creating a Society That is Inclusive for All People at All Times (April 1, 2024)
- [New Report] Policy Priorities for Super-Ageing Japan: Health Innovation and Economic Growth in the COVID-19 Pandemic Era (February 24, 2021)
Featured Posts
-
2024-09-26
[Registration Open] HGPI Salon Special Edition “The 2024 U.S. Presidential Election’s Impact on Japan’s Healthcare Policies: Future Implications for U.S.-China Relations and U.S.-Japan Cooperation” (October 28, 2024)
-
2024-10-07
[Registration Open] International Dialogue “Fostering Community and Citizen-led Approaches to AMR: Lessons from Antibiotic Smart Sweden” (October 25, 2024)
-
2024-10-07
[Registration Open] Planetary Health Expert Meeting “Building the Future of Healthcare: A Vision for Sustainable and Resilient Health Systems with GGHH” (November 5, 2024)
-
2024-10-09
[Registration Open] HGPI Salon Special Edition “Overcoming Infectious Diseases through Partnership: Focusing on examples of promoting technology transfer of antimicrobial agents” (October 21, 2024)
-
2024-10-09
[Registration Open] (Webinar) The 128th HGPI Seminar “Viewing Healthcare Disparities Through the Lens of Breast Cancer Treatment” (October 29, 2024)